Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

ProFunds Biotechnology UltraSector Fund Investor Class (BIPIX)

76.33
Net Asset Value
-0.97%
1 Day
+20.78%
Year-to-Date
Overall Morningstar Rating
Trading-leveraged equity
Style or Category
No Load
Sales Expenses
1.57%
Expense Ratio
High
Morningstar Risk Rating™
Investment Objective The investment seeks daily investment results, before fees and expenses, that correspond to one and one-half times (1.5x) the daily performance of the Dow Jones U.S. BiotechnologySM Index. The fund invests in securities and derivatives that the adviser believes, in combination, should have similar daily return characteristics as one and one-half times (1.5x) the daily return of the index. The index measures the performance of the biotechnology sector of the U.S. equity market. It is non-diversified.

Performance

1 month+4.73% 3 years+60.52%
3 months+10.05% 5 years+50.90%
1 year+49.93% Since inception+9.05%
Data through --

Peer Comparisonvs. Trading-leveraged equity

 BIPIXCategory
Performance 5-yr return+50.90%+16.48%
Expense ratio1.57%2.05%
Risk 5 year sharpe ratio1.84--
Net assets$798.3M$82.7M
Average market cap$64.1B--
Average P/E25.9--
Portfolio turnover47%47%

There are thousands of mutual funds to choose from. Get Money Magazine’s picks in all major categories.

Fund Management and Purchase Info

Fund familyProFunds
Fund manager & tenureMichael Neches / 1 Years
Minimal initial investment$15,000.00
Minimum IRA investment$15,000.00

Holdings

U.S. stock61.93%
Cash38.07%
International stock0.00%
Fixed income0.00%
Other0.00%
Top 5 Sectors
Portfolio weighting
Healthcare 100.00%
Business service 0.00%
Consumer goods 0.00%
Consumer service 0.00%
Energy 0.00%
Top 10 Holdings
Portfolio weighting
GILD Gilead Sciences11.67%
AMGN Amgen8.54%
ABBV AbbVie7.09%
CELG Celgene7.02%
BIIB Biogen6.80%
ALXN Alexion Pharmaceuticals Inc2.68%
REGN Regeneron Pharmaceuticals2.29%
ILMN Illumina Inc2.06%
VRTX Vertex Pharmaceuticals Inc1.95%
BMRN Biomarin Pharmaceutical Inc1.13%